Category: CBSA News

The 2022 legislative session, the Second Regular Session of the 73rd General Assembly, has concluded. It was an unprecedented session that  began with the legislature having significant financial...

CBSA is pleased to share news of a significant win at the State Capitol for our life sciences community. Late last night, the legislature voted to reauthorize the Advanced Industries Tax Credit Progra...

The legislative session is scheduled to end on Wednesday, May 11th, or in about 12 days. As we enter the final stretch, the CBSA team continues to weigh in on key legislation and advocate on behalf of...

Atara Biotherapeutics is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumor...

Guest Post by Peter Adams, Executive Director, Rockies Venture Club Anyone who has been watching valuations in life sciences deals over the past couple of years knows that median valuations in life sc...

Executives from JP Morgan Chase & Company, AGC Biologics, Innosphere Ventures, GelSana, and Terumo Blood and Cell Technologies Join Board Denver – Colorado BioScience Association (CBSA), which cre...

CBSA is committed to keeping our community updated on issues that impact life sciences. Our Policy + Advocacy team is reviewing newly proposed legislation that could directly affect life sciences comp...

Guest Post by Peter Adams, Executive Director, Rockies Venture Club I am often surprised when I meet investors who claim that they invest in just about anything but life sciences.  Last year heal...

CBSA and our national partners support the renewal of the critically important Medical Device User Fee Amendments (MDUFA). After months of negotiations among the FDA and industry advocacy groups, incl...

A longstanding policy priority for CBSA is supporting our ecosystem’s need for increased access to capital. Through our Capital + Growth efforts, we work closely with public and private partners to ac...